



OPEN ACCESS

EDITED BY

Vita Golubovskaya,
ProMab Biotechnologies, United States

REVIEWED BY

Marko Barešić,
University Hospital Centre Zagreb,
Croatia
Tomoya Nakajima,
Kyoto University, Japan
Daniela Faria,
Unidade Local Saude do Alto Minho,
Portugal

*CORRESPONDENCE

Luca Cantarini
✉ cantariniluca@hotmail.com
Antonio Vitale
✉ vitale.reumatologia@gmail.com

RECEIVED 30 December 2025

REVISED 12 February 2026

ACCEPTED 23 April 2026

PUBLISHED 13 May 2026

CITATION

Vitale A, Caggiano V, Sbalchiero J, Gavioli F, Lopalco G, Ragab G, Guerriero S, Almaglouth I, Tufan A, Giacomelli R, Direskeneli H, Ruscitti P, Hatemi G, Carubbi F, Batu ED, Ozen S, Sota J, Giardini HAM, Frassi M, Sfrikakis PP, Morrone M, Gatti F, Maher A, Mahmoud AA-MA, Dammacco R, Kucuk H, Kardas RC, Cakir IY, Corcia LPd, Öner FA, Sevik G, Gentile M, Karakoc A, Alunno A, Emreol HE, Crisafulli F, Tektonidou M, Ciccio F, Thabet M, Bugatti S, Milanesi A, Chimenti MS, Monosi B, Piga M, Floris A, Hinojosa-Azaola A, Guaracha-Basañez GA, Chighizola CB, Hernández-Rodríguez J, Cattalini M, Govoni M, Viapiana O, Civino A, Opris-Belinski D, Gaggiano C, Talarico R, Giardina A, Emmi G, Puttini PS, Maggio MC, Parronchi P, Portincasa P, de-la-Torre A, Cardona-López J, Gentileschi S, Mauro A, Sebastiani GD, Gicchino MF, Şahin A, Rigante D, Bilgin E, Del Giudice E, Breda L, De Paulis A, Lo Gullo A, Erten Ş, Tharwat S, Fotis L, Armin M, Insalaco A, Karamanakis A, Conforti A, Gündüz ÖS, Moshirif A, Li Gobbi F, Costi S, Bartoloni E, Barone P, Guiducci S, González-García A, Rodríguez IH, Conti G, Iagnocco A, Önen F, Al-Mayouf SM, Hatemi AI, Balistreri A, Fabiani C and Cantarini L (2026) Risk of intestinal involvement in mucocutaneous-onset Behçet's disease: data from the AIDA network registry. *Front. Immunol.* 17:1778171. doi: 10.3389/fimmu.2026.1778171

Risk of intestinal involvement in mucocutaneous-onset Behçet's disease: data from the AIDA network registry

Antonio Vitale^{1*}, Valeria Caggiano¹, Jessica Sbalchiero¹, Francesco Gavioli¹, Giuseppe Lopalco², Gaafar Ragab^{3,4}, Silvana Guerriero⁵, Ibrahim Almaglouth⁶, Abdurrahman Tufan⁷, Roberto Giacomelli⁸, Haner Direskeneli⁹, Piero Ruscitti¹⁰, Gülen Hatemi¹¹, Francesco Carubbi¹², Ezgi Deniz Batu¹³, Seza Ozen¹³, Jurgen Sota¹, Henrique Ayres Mayrink Giardini¹⁴, Micol Frassi¹⁵, Petros P Sfrikakis¹⁶, Maria Morrone², Federica Gatti², Amina Maher^{3,4}, Ayman Abdel-Monem Ahmed Mahmoud^{3,4}, Rosanna Dammacco⁵, Hamit Kucuk⁷, Riza Can Kardas⁷, Ibrahim Yahya Cakir⁷, Letizia Pia di Corcia⁸, Fatma Alibaz Öner⁹, Gizem Sevik⁹, Martina Gentile¹⁰, Alican Karakoc¹¹, Alessia Alunno¹², Hulya Ercan Emreol¹³, Francesca Crisafulli¹⁵, Maria Tektonidou¹⁶, Francesco Ciccio¹⁷, Maissa Thabet¹⁸, Serena Bugatti¹⁹, Alessandra Milanesi¹⁹, Maria Sole Chimenti²⁰, Benedetta Monosi²⁰, Matteo Piga²¹, Alberto Floris²¹, Andrea Hinojosa-Azaola²², Guillermo Arturo Guaracha-Basañez²², Cecilia Beatrice Chighizola^{23,24}, José Hernández-Rodríguez²⁵, Marco Cattalini²⁶, Marcello Govoni²⁷, Ombretta Viapiana²⁸, Adele Civino²⁹, Daniela Opris-Belinski³⁰, Carla Gaggiano¹, Rosaria Talarico³¹, Annarita Giardina³², Giacomo Emmi^{33,34}, Piercarlo Sarzi Puttini³⁵, Maria Cristina Maggio³⁶, Paola Parronchi³⁷, Piero Portincasa³⁸, Alejandra de-la-Torre³⁹, Juanita Cardona-López³⁹, Stefano Gentileschi¹, Angela Mauro^{40,41}, Gian Domenico Sebastiani⁴², Maria Francesca Gicchino⁴³, Ali Şahin⁴⁴, Donato Rigante^{45,46}, Emre Bilgin⁴⁷, Emanuela Del Giudice⁴⁸, Luciana Breda⁴⁹, Amato De Paulis^{50,51}, Alberto Lo Gullo⁵², Şükran Erten⁵³, Samar Tharwat^{54,55}, Lampros Fotis⁵⁶, Maier Armin⁵⁷, Antonella Insalaco⁵⁸, Anastasios Karamanakis⁵⁹, Alessandro Conforti⁶⁰, Özgül Soysal Gündüz⁶¹, Abdelhfeez Moshirif⁶², Francesca Li Gobbi⁶³, Stefania Costi²⁴, Elena Bartoloni⁶⁴, Patrizia Barone⁶⁵, Serena Guiducci⁶⁶, Andrés González-García⁶⁷, Inés Hernanz Rodriguez⁶⁸,

**Giovanni Conti⁶⁹, Annamaria Iagnocco⁷⁰, Fatos Önen⁷¹,
Sulaiman M. Al-Mayouf⁷², Ali İbrahim Hatemi⁷³,
Alberto Balistreri⁷⁴, Claudia Fabiani⁷⁵ and Luca Cantarini^{1*}**

¹Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences Department of Medical Sciences, Surgery and Neurosciences, University of Siena and Azienda Ospedaliero-Universitaria Senese, Siena, Italy, ²Department of Precision and Regenerative Medicine and Ionian Area (DiMePRE-J) Policlinic Hospital, University of Bari, Bari, Italy, ³Internal Medicine Department, Rheumatology and Clinical Immunology Unit, Faculty of Medicine, Cairo University, Giza, Egypt, ⁴Faculty of Medicine, Newgiza University, 6th of October, Giza, Egypt, ⁵Department of of Translational Biomedicine and Neuroscience (DiBraiN), University of Bari, Bari, Italy, ⁶Rheumatology Unit, Department of Medicine, King Saud University, Riyadh, Saudi Arabia, ⁷Division of Rheumatology, Department of Internal Medicine, Gazi University Hospital, Ankara, Türkiye, ⁸Rheumatology, Immunology and Clinical Medicine Unit, Department of Medicine, Università Campus Bio-Medico di Roma, Rome, Italy, ⁹Department of Internal Medicine, Division of Rheumatology, School of Medicine, Marmara University, Istanbul, Türkiye, ¹⁰Rheumatology Unit, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy, ¹¹Department of Internal Medicine, Division of Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Türkiye, ¹²University of L'Aquila, Department of Life, Health & Environmental Sciences, Internal Medicine and Nephrology Division, ASL1 Avezzano-Sulmona-L'Aquila, San Salvatore Hospital, L'Aquila, Italy, ¹³Pediatric Rheumatology Unit, Department of Pediatrics, Hacettepe University School of Medicine, Ankara, Türkiye, ¹⁴Rheumatology Division, Faculdade de Medicina, Hospital das Clínicas (HCFMUSP), Universidade de São Paulo, São Paulo, Brazil, ¹⁵Rheumatology and Clinical Immunology, Spedali Civili and Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, ¹⁶Joint Academic Rheumatology Program, National and Kapodistrian University of Athens Medical School, Athens, Greece, ¹⁷Department of Precision Medicine, Università Degli Studi Della Campania Luigi Vanvitelli, Naples, Italy, ¹⁸Internal Medicine Department, Farhat Hached University Hospital, Faculty of Medicine of Sousse, University of Sousse, Sousse, Tunisia, ¹⁹Department of Internal Medicine and Therapeutics, Università di Pavia and Division of Rheumatology, Fondazione Istituto di ricovero e cura a carattere scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy, ²⁰Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy, ²¹Rheumatology Unit, Department of Medical Sciences, University and AOU of Cagliari, Cagliari, Italy, ²²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas Y Nutrición Salvador Zubirán, Mexico City, Mexico, ²³Pediatric Rheumatology Unit, Azienda Socio-Sanitaria Territoriale (ASST) Gaetano Pini Centro Specialistico Ortopedico Traumatologico (CTO), Milan, Italy, ²⁴Department of Clinical Sciences and Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, University of Milan, Milan, Italy, ²⁵Autoinflammatory Diseases Clinical Unit, Department of Autoimmune Diseases, Hospital Clinic of Barcelona, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona, Barcelona, Spain, ²⁶Pediatric Clinic, University of Brescia and Spedali Civili di Brescia, Brescia, Italy, ²⁷Rheumatology Unit, Department of Medical Sciences, Azienda Ospedaliero-Universitaria S. Anna - Ferrara, University of Ferrara, Ferrara, Italy, ²⁸Rheumatology Unit, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy, ²⁹Pediatric Rheumatology and Immunology Unit, Vito Fazzi Hospital, Lecce, Italy, ³⁰Rheumatology and Internal Medicine Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ³¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ³²UOC Medicina Interna, Ambulatorio di Reumatologia, Azienda ospedaliera di rilievo nazionale e di alta specializzazione (ARNAS) Civico Di Cristina Benfratelli, Palermo, Italy, ³³Department of Medical, Surgical and Health Sciences, and Clinical Medicine and Rheumatology Unit, Cattinara University Hospital, University of Trieste, Trieste, Italy, ³⁴Centre for Inflammatory Diseases, Department of Medicine, Monash Medical Centre, Monash University, Clayton, VIC, Australia, ³⁵Rheumatology Unit, Ospedale Sacco, Milan, Italy, ³⁶University Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE) "G. D'Alessandro", University of Palermo, Palermo, Italy, ³⁷Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ³⁸Clinica Medica "A. Murri", Division of Internal Medicine, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRE-J), University of Bari Aldo Moro, Bari, Italy, ³⁹Neuroscience Research Group (NEUROS), Neurovitae Center for Neuroscience, Institute of Translational Medicine (IMT), School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia, ⁴⁰Department of Biomedical and Clinical Sciences, Fatebenefratelli Hospital, Università di Milano, Milan, Italy, ⁴¹Pediatric Rheumatology Unit, Department of Childhood and Developmental Medicine, Fatebenefratelli-Sacco Hospital, Milan, Italy, ⁴²Unità operativa complessa (U.O.C.) Reumatologia, Ospedale San Camillo-Forlanini, Rome, Italy, ⁴³Department of Woman, Child and of General and Specialized Surgery, University of Campania "Luigi Vanvitelli", Naples, Italy, ⁴⁴Division of Rheumatology, Department of Internal Medicine, Sivas Cumhuriyet University Medical Faculty, Sivas, Türkiye, ⁴⁵Department of Life Sciences and Public Health, Fondazione Policlinico Universitario A. Gemelli Istituto di ricovero e cura a carattere scientifico (IRCCS), Rome, Italy, ⁴⁶Rare Diseases and Periodic Fevers Research Centre, Università Cattolica Sacro Cuore, Rome, Italy, ⁴⁷Division of Rheumatology, Faculty of Medicine, Sakarya University, Sakarya, Türkiye, ⁴⁸Department of Maternal Infantile and Urological Sciences, Sapienza University of Rome, Polo Pontino, Rome, Italy, ⁴⁹Department of Paediatrics, University of Chieti-Pescara, Chieti, Italy, ⁵⁰Department of Translational Medical Sciences, Section of Clinical Immunology, University of Naples Federico II, Naples, Italy, ⁵¹Center for Basic and Clinical Immunology Research (CISI), WAO Center of Excellence, University of Naples Federico II, Naples, Italy, ⁵²Unit of Rheumatology, Department of Medicine, Azienda ospedaliera di rilievo nazionale e di alta specializzazione (ARNAS) Garibaldi Hospital, Catania, Italy, ⁵³Department of Rheumatology, Faculty of Medicine Ankara City Hospital, Ankara Yildirim Beyazit

Universitesi, Ankara, Türkiye, ⁵⁴Rheumatology and Immunology Unit, Internal Medicine Department, Mansoura University, Mansoura, Egypt, ⁵⁵Department of Internal Medicine, Faculty of Medicine, Horus University, New Damietta, Egypt, ⁵⁶Department of Pediatrics, Attikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece, ⁵⁷Rheumatology Unit, Department of Medicine, Central Hospital of Bolzano, Bolzano, Italy, ⁵⁸Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, Istituto di ricovero e cura a carattere scientifico (IRCCS), Rome, Italy, ⁵⁹Department of Rheumatology, "Evangelismos" General Hospital, Athens, Greece, ⁶⁰Ospedale San Paolo di Civitavecchia, U.O. Medicina Generale, ASL Roma 4, Rome, Italy, ⁶¹Division of Rheumatology, Department of Internal Medicine, School of Medicine, Manisa Celal Bayar University, Manisa, Türkiye, ⁶²Rheumatology Department, Faculty of Medicine, Al-Azhar University, Assiut, Egypt, ⁶³Rheumatology Unit, Hospital S. Giovanni di Dio, Azienda USL-Toscana Centro, Florence, Italy, ⁶⁴Rheumatology Unit, Department of Medicine and Surgery, University of Perugia, Perugia, Italy, ⁶⁵Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy, ⁶⁶Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ⁶⁷Systemic Autoimmune Diseases Unit, Department of Internal Medicine, Hospital Universitario Ramón y Cajal, Instituto Ramon y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain, ⁶⁸Department of Ophthalmology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ⁶⁹Pediatric Nephrology and Rheumatology Unit, Azienda Ospedaliero Universitaria (AOU) G Martino, Messina, Italy, ⁷⁰Academic Rheumatology Center, Dipartimento Scienze Cliniche e Biologiche, Università degli Studi di Torino, Turin, Italy, ⁷¹Department of Internal Medicine, Division of Rheumatology, School of Medicine, Dokuz Eylül University, İzmir, Türkiye, ⁷²Department of Pediatrics, King Faisal Specialist Hospital and Research Center, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia, ⁷³Department of Internal Medicine, Division of Gastroenterology, Cerrahpaşa Medical School, Istanbul University-Cerrahpaşa, Istanbul, Istanbul, Türkiye, ⁷⁴Bioengineering and Biomedical Data Science Lab, Department of Medical Biotechnologies, University of Siena, Siena, Italy, ⁷⁵Ophthalmology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena and Azienda Ospedaliero-Universitaria Senese, Siena, Italy

Objective: Behçet's disease (BD) may initially manifest solely with mucocutaneous involvement. This study aimed to identify demographic and clinical factors associated with subsequent intestinal involvement in patients presenting exclusively with mucocutaneous manifestations during early disease stages.

Methods: Data were obtained from the International AutoInflammatory Disease Alliance Network registry dedicated to BD; a Bayesian statistical approach was employed to address the limited sample size resulting from subgroup stratifications.

Results: In total, 328 BD patients with exclusively mucocutaneous onset were enrolled; of these, 46 (14%) developed intestinal involvement over time. The risk of ocular involvement was higher among patients with intestinal manifestations (OR: 3.02, 95% CrI: 1.24–6.08; posterior probability: 99.3%). Minor aphthous ulcers without major aphthosis were protective towards intestinal involvement (OR: 0.47, 95% CrI: 0.22–0.98; posterior probability: 97.98%). Conversely, major aphthous ulcers increased the risk (OR: 3.25, 95% CrI: 1.50–7.02; posterior probability: 99.7%), along with the combination of oral major aphthosis with: i) genital aphthosis (OR = 2.77, 95%CrI: 1.14–6.58; posterior probability: 98.45%); ii) pseudofolliculitis (OR = 3.18, 95%CrI: 1.15–8.33; posterior probability: 98.72%); iii) genital aphthosis plus pseudofolliculitis (OR = 5.22, 95%CrI: 1.71–16.35; posterior probability of 99.77%). Pseudofolliculitis plus cutaneous manifestations other than erythema nodosum were protective against intestinal involvement (OR = 0.01, 95%CrI: 0.0–0.98; posterior probability: 97.55%).

Conclusion: Major aphthosis was the strongest factor associated with intestinal involvement in BD patients initially presenting with mucocutaneous symptoms only. In such patients, intestinal involvement correlated with increased risk of ocular inflammation.

KEYWORDS

gut, inflammation, precision medicine, predictors, risk factors

Highlights

- Major oral aphthosis is the strongest predictor of subsequent intestinal involvement in Behçet's disease patients who initially present with only mucocutaneous symptoms.
- Specific combinations of mucocutaneous features, particularly major oral aphthosis with genital aphthosis and/or pseudofolliculitis, significantly increase the risk of intestinal manifestations, while minor aphthosis appears protective.
- Intestinal involvement is linked to a higher likelihood of ocular inflammation, suggesting overlapping pathogenic mechanisms and highlighting the need for careful multi-disciplinary monitoring in high-risk patients.

Introduction

Behçet's syndrome (BD) is a multifactorial disease characterised by a heterogeneous spectrum of clinical features including mucocutaneous, articular, ocular, vascular, neurological, and gastrointestinal manifestations (1). However, BD may initially present clinical manifestations limited to mucocutaneous involvement, including recurrent oral and genital ulcers, pseudofolliculitis, erythema nodosum, skin ulcers, pyoderma gangrenosum, and other polymorphic cutaneous eruptions (2). Nevertheless, the disease may later evolve to major organ involvement, potentially affecting the eye, the vascular system, the central nervous system (CNS), and the gastrointestinal tract (3, 4). Intestinal involvement may manifest with features closely resembling inflammatory bowel diseases, particularly Crohn's disease (5). Typical lesions include deep, well-demarcated ulcers, most commonly located in the terminal ileum and cecum, although any segment of the gastrointestinal tract may be affected (6, 7). Abdominal pain and diarrhoea represent the most common clinical symptoms, complicated by intestinal perforation or massive hemorrhage in severe cases (1). Intestinal involvement is often associated with greater BD severity and can be life-threatening, thus requiring the use of immunosuppressive or biotechnological therapies (8). This progression highlights the importance of regular clinical monitoring even in patients initially presenting with an apparently benign phenotype. In this regard, it is useful to identify clinical features that may help distinguish, among patients presenting mucocutaneous involvement only, those who are more likely to develop intestinal involvement. This has important practical implications for assessing the risk of developing a potentially disabling and life-threatening complication, which warrants closer follow-up and an appropriate therapeutic approach. Therefore, the present study was conducted to identify clinical characteristics associated with an increased risk of developing intestinal involvement in patients presenting mucocutaneous manifestations as the sole form of BD in the early stages.

Materials and methods

Demographic, genetic and clinical data were obtained from the International AutoInflammatory Disease Alliance (AIDA) Network

registry dedicated to BD (9). All participants fulfilled the classification criteria established by the International Study Group (ISG) and/or the International Criteria for BD (ICBD) (10, 11).

For this analysis, patients whose initial disease presentation was restricted exclusively to mucocutaneous involvement were selected. Specifically, eligible patients presented with oral aphthosis, genital ulcers, and/or BD-related cutaneous lesions, without any evidence of ocular, gastrointestinal, vascular, or CNS involvement for at least 12 months following disease onset. Disease onset was defined as the time point at which the patient first fulfilled the established classification criteria. Intestinal involvement was defined as the presence of inflammation and/or ulceration within the gastrointestinal tract, with occurrence of abdominal pain, persistent diarrhea, hematochezia, intestinal occlusion or stenosis, or fistulas. In this context, recurrent diarrhea and abdominal pain were considered relevant only when accompanied by a significant elevation in faecal calprotectin levels (≥ 130 mg/kg). Guided by clinical necessity, an endoscopy was performed to identify any macroscopic lesions or histological alterations compatible with intestinal inflammatory involvement associated with BD. Alternative causes of intestinal inflammation or ulceration were meticulously ruled out through targeted investigations tailored to each individual clinical presentation.

Patients were subsequently stratified according to whether they developed gastrointestinal involvement over the course of the disease. A comprehensive assessment was conducted, including demographic and clinical variables, human leukocyte antigen (HLA)-B51 status, the size and number of concomitant oral and genital ulcers, as well as the full spectrum of BD-related cutaneous manifestations. BD activity at the start of the disease was evaluated using the transformed BD current activity form (BDCAF), if available within two years from the disease onset (12).

Oral and genital ulcer count at disease onset was categorized into three groups: 1–2 lesions, 3–5 lesions, and more than 5 lesions. Based on size-based classifications of oral ulcers proposed in the literature (13), oral aphthae were further classified into minor (<10 mm in diameter), major (>10 mm), and herpetiform (numerous, small, and clustered lesions).

Statistical analysis included descriptive methods such as mean, median, standard deviation (SD), interquartile range, frequency counts, and corresponding percentages. A Bayesian logistic regression framework was employed to assess the association between clinical and demographic variables and the development of intestinal involvement over the course of the disease. The presence or absence of intestinal involvement was modeled as the dependent variable, while individual demographic, clinical, and mucocutaneous features were entered one at a time as independent variables. Models were fitted using the *brms* package in R Studio software, which interfaces with Stan for Bayesian inference via Hamiltonian Monte Carlo. Each model estimated the posterior distribution of the log-odds of intestinal involvement as a function of the selected covariate. A weakly informative normal prior (mean = 0, SD = 5) was applied to all regression coefficients to regularize estimation while avoiding strong assumptions. Each model was run using four Markov chains, each with 2,000 iterations (including 1,000 warm-up and 1,000 sampling steps), ensuring proper convergence and

sufficient exploration of the posterior distribution. Posterior summaries were reported as means and 95% credible intervals (CrIs). In addition, the posterior probability of a positive (or negative) association was computed directly from the posterior draws, allowing for intuitive probabilistic interpretation of effect estimates. Odds ratios (ORs) and their corresponding 95% CrIs were obtained by exponentiating the posterior distributions of the regression coefficients. Associations were considered statistically significant when the 95% CrI excluded the null value ($OR = 1$), and/or when the posterior probability exceeded 97.5%. Variables with posterior probabilities above 95% were considered to show a trend toward significance. All models were adjusted for potential confounders, including maximum disease duration (meant as the time between disease onset and the last visit collected in the AIDA registry), use of conventional disease-modifying antirheumatic drugs (cDMARDs), and anti-tumor necrosis factor (TNF) biotechnological agents.

For all variables that were either statistically significant or showed a trend toward, marginal effects were calculated to quantify the absolute change in the predicted probability of intestinal involvement associated with the presence or absence of the given characteristic.

This Bayesian approach was favored over frequentist methods to provide more informative, flexible, and probabilistically interpretable estimates, particularly given the modest sample size and subgroup stratifications.

When evaluating the effect of combinations of mucocutaneous variables on intestinal involvement using Bayesian logistic regression models, only associations observed in at least 10 patients were considered to ensure statistical stability.

Results

A total of 328 BD patients with exclusively mucocutaneous involvement at the disease onset were enrolled; of these, 46 (14%) developed intestinal inflammatory involvement over time, as better described in Table 1. Among patients developing intestinal involvement over time, 10 (21.7%) also exhibited ocular inflammation, 3 (6.5%) developed vascular involvement and 1 (2.2%) CNS involvement. Bayesian analysis yielded an OR of 3.02 (95% CrI: 1.24-6.08) for the association between ocular and intestinal involvement in BD, with a posterior probability of 99.3% that ocular manifestations are more frequent among patients developing intestinal involvement. In contrast, no substantial evidence of an association was found between intestinal and vascular involvement ($OR: 0.63$, 95% CrI: 0.2-2.8, posterior probability: 74.9%), and between intestinal and CNS involvement ($OR: 1.36$, 95% CrI: 0.14-4.44, posterior probability: 52.1%).

Table 2 presents the ORs and their corresponding 95% CrI, along with the probabilities of association between the specific variables assessed in this study and the development of intestinal involvement. The presence of minor aphthous ulcers with no major aphthosis was found to be protective against the development of intestinal involvement ($OR = 0.47$, 95% CrI: 0.22-0.98), with this assertion associated to a posterior probability of 97.98%.

Conversely, the presence of major aphthous ulcers was associated with an increased predisposition to gut involvement ($OR = 3.25$, 95% CrI: 1.50-7.02), an assertion associated with a posterior probability of 99.7%.

Both HLA-B51 haplotype and Caucasian ethnicity showed a strong tendency towards a significant association with the development of intestinal involvement. In particular, HLA-B51 positivity showed an odds ratio of 2.05 (95% CrI: 0.99-4.44) for intestinal involvement, with a posterior probability of 97.2% to be associated to gastrointestinal involvement. Conversely, HLA-B51 negativity had an odds ratio of 0.49 (95% CrI: 0.22-1.04), with a posterior probability of 96.5% to be protective. Caucasian ethnicity showed an odds ratio of 2.45 (95% CrI: 0.99-6.66) for gut involvement, with a posterior probability of 97.42%.

Table 3 presents the results from Bayesian regression models investigating the association between intestinal involvement and various combinations of mucocutaneous manifestations observed in the early stages of BD, after adjusting for follow-up duration and the use of cDMARDs or anti-TNF biologics. Specifically, the combination of oral major aphthous ulcerations and genital aphthosis was associated with an increased predisposition to intestinal involvement ($OR = 2.77$, 95% CrI: 1.14-6.58), with a posterior probability of 98.45%. Similarly, the co-occurrence of oral major aphthous ulcerations and pseudofolliculitis showed an increased predisposition to intestinal involvement ($OR = 3.18$, 95% CrI: 1.15-8.33), with a posterior probability of 98.72%. Furthermore, the triple association of oral major aphthous ulcerations, genital aphthosis, and pseudofolliculitis showed an even stronger predisposition to gut involvement ($OR = 5.22$, 95% CrI: 1.71-16.35), supported by a posterior probability of 99.77%. Conversely, the combination of pseudofolliculitis and cutaneous manifestations other than erythema nodosum was strongly associated with a protective effect against gut involvement ($OR = 0.01$, 95% CrI: 0.0-0.98), with a posterior probability of 97.55%.

Figure 1 displays a balance plot that illustrates the expected probabilities of gut involvement, conditional on the presence or absence of each variable significantly associated with intestinal inflammatory involvement. This plot also shows the marginal effects, which quantify the change in probability associated with the presence versus absence of each variable.

Discussion

Intestinal involvement in BD patients, occurring in about 10-19% of cases (14), may significantly impair quality of life and potentially lead to serious and life-threatening complications (15). This can occur even in individuals initially presenting with a mild clinical picture and no major organ involvement in the early stage of the disease.

Independent factors associated to intestinal involvement in BD include male gender, higher disease activity, elevated inflammatory markers, and low haemoglobin (16). However, the present study aimed to identify factors associated with the development of intestinal involvement in the specific subset of patients with no

TABLE 1 Demographic and clinical characteristics of the 328 patients with Behçet's disease who initially presented with only mucocutaneous manifestations, and the type of gastrointestinal involvement subsequently reported in 46 patients during later stages of the disease.

Patients' features	Patients without gut involvement (n=282)	Patients later developing gut involvement (n=46)
Sex (F/M)	149/133	33/13
Country of origin		
Brazil, n (%)	7 (2.5)	0 (0)
Egypt, n (%)	32 (11.4)	3 (6.5)
Greece, n (%)	7 (2.5)	1 (2.2)
Italy, n (%)	160 (56.7)	39 (84.8)
Libya, n (%)	1 (0.4)	0 (0)
Mexico, n (%)	2 (0.7)	1 (2.2)
Romania, n (%)	3 (1.1)	0 (0)
Saudi Arabia, n (%)	17 (6)	1 (2.2)
Spain, n (%)	2 (0.7)	1 (2.2)
Tunisia, n (%)	5 (1.8)	0 (0)
Turkey, n (%)	44 (15.6)	0 (0)
Yemen, n (%)	2 (0.7)	0 (0)
Ethnicity#		
Caucasian, n (%)	193 (68.44%)	40 (86.95%)
Arab, n (%)	55 (19.50%)	5 (10.87%)
Hispanic, n (%)	5 (1.77%)	1 (2.17%)
Other, n (%)	7 (2.48%)	0 (0.0%)
Age at disease onset, years (mean ± SD)	29.53 (± 13.99)	28.76 (± 14.42)
Age at disease diagnosis, years (mean ± SD)	34.73 (± 13.96)	35.21 (± 13.56)
HLA-B51 positivity, n (%)*	128 (45.40%)	29 (63.04%)
Positive family history, n (%)	29 (10.28%)	6 (13.04%)
Initial BDCAF value, mean (IQR)	5 (4)	7 (3)
Oral aphthosis features at baseline[§]		
Concurrent oral ulcers (1–2 lesions)	68 (24.11%)	6 (13.04%)
Concurrent oral ulcers (3–5)	82 (29.07%)	19 (41.3%)
Concurrent oral ulcers (>5)	40 (14.18%)	7 (15.21%)
Oral Minor aphthous ulcerations (<10mm)	143 (50.71%)	16 (34.78%)
Oral Major aphthous ulcerations (>10mm)	48 (17.02%)	18 (39.13%)
Oral herpetiform ulcerations	8 (2.83%)	2 (4.34%)
Genital aphthosis features at baseline		
Genital aphthosis	187 (66.31%)	33 (71.74%)
Concurrent genital ulcers (1–2 lesions) ^{§§}	97 (34.40%)	15 (32.6%)
Concurrent genital ulcers (3–5 lesions) ^{§§}	27 (9.57%)	5 (10.87%)

(Continued)

TABLE 1 Continued

Patients' features	Patients without gut involvement (n=282)	Patients later developing gut involvement (n=46)
Genital aphthosis features at baseline		
Concurrent genital ulcers (>5 lesions) ^{§§}	8 (2.83%)	0 (0.0%)
Skin manifestations at baseline		
Skin involvement	161 (57.09%)	31 (67.39%)
Pseudofolliculitis	117 (41.49%)	18 (39.13%)
Erythema nodosum	56 (19.85%)	12 (26.08%)
Infrequent skin rash	24 (8.51%)	3 (6.52%)
Gut involvement		
Persistent diarrhea	0 (0.0%)	27 (58.69%)
Hematochezia	0 (0.0%)	3 (6.52%)
Gastrointestinal occlusion	0 (0.0%)	1 (2.17)
Recurrent abdominal pain without peritonism	6 (2.12%)	15 (32.6%)
Recurrent abdominal pain with peritonism	0 (0.0%)	1 (2.17%)
Macroscopic inflammatory lesions at endoscopy**	0 (0.0%)	12 (26.08%)
Macroscopic vasculitic lesions at endoscopy**	0 (0.0%)	1 (2.17%)
Ocular involvement over time	26 (9.2%)	10 (21.7%)
Vascular involvement over time	11 (3.9%)	3 (6.45%)
CNS involvement over time	9 (3.2%)	1 (2.17%)

#, not provided in 22 cases; *in 60 cases HLA-B evaluation not performed; **Percentage referred to the 47 patients undergoing endoscopy; §, information provided in 222 (68%) cases; §§, information provided in 152 out of 220 cases with genital ulcers. BDCAF, Behçet's Disease Current Activity Form; CNS, central nervous system; F, females; HLA, human leukocyte antigen; M, males; SD, standard deviation.

major organ manifestations at disease onset. Particular attention was given to potential associations with mucocutaneous clinical features and patients' demographic characteristics. The first prominent association observed was a higher frequency of ocular involvement among patients who also developed intestinal manifestations, suggesting a mutual predisposition for the co-occurrence of ocular and intestinal involvement in BD. This assertion, supported with 99.3% posterior probability at the current Bayesian analysis, stands in contrast to earlier findings reporting a lack of overlap between ocular and intestinal involvement in BD (14). However, this aforementioned finding was reported in a general cohort of BD Chinese patients, while the present study specifically investigated patients with mucocutaneous manifestations as their sole clinical presentation at disease onset. Also, the frequency of intestinal involvement in BD varies widely across populations, while patients from East Asian countries remain underrepresented in the AIDA registry, at current. In contrast, Hispanic, Arab, and Caucasian ethnicities are more prominently represented. When

TABLE 2 Results of Bayesian regression analyses evaluating the association between intestinal involvement (dependent variable) and the singularly assessed variables listed in the first column (independent variable).

Variables singularly assessed	OR (95% CrI)	P ($\beta > 0$)	P ($\beta < 0$)
Age at disease onset	1 (0.97-1.02)	41.15%	58.85%
Age at diagnosis	1 (0.98-1.03)	55.62%	44.38%
Sex (male)	0.6 (0.27-1.24)	9.4%	90.6%
Sex (female)	1.68 (0.79-3.7)	91.6%	8.4%
Body mass index, Kg	0.98 (0.95-1.01)	8.2%	91.8%
Smoking history	1.13 (0.44-2.7)	62.2%	27.8%
HLA-B51 positivity	2.05 (0.99-4.44)	97.2%	2.8%
HLA-B51 negativity	0.49 (0.22-1.04)	3.5%	96.5%
Positive family history	1.97 (0.6-5.8)	50.2%	49.8%
Negative family history	0.49 (0.22-1.04)	3.5%	96.5%
Initial BDCAF value#	1.25 (0.88-1.8)	88.8%	11.2%
Oral ulcers 1-2	0.43 (0.14-1.19)	5.4%	94.6%
Oral ulcers 3-5	1.73 (0.70-4.22)	89.5%	10.5%
Oral ulcers >5	1.11 (0.36-3.06)	58.67%	41.33%
Genital ulcers 1-2	1.04 (0.33-3.56)	51.5%	48.5%
Genital ulcers 3-5	1.52 (0.41-5.31)	74.5%	25.5%
Genital ulcers >5	0.01 (0-1.16)	3.42%	96.58%
Genital ulcers yes/no	1.63 (0.70-4.01)	86.5%	13.5%
Herpetiform aphthous ulcers	1.75 (0.21-10.8)	72.7%	27.3%
Minor aphthous	0.47 (0.22-0.98)	2.02%	97.98%
Major aphthous	3.25 (1.50-7.02)	99.7%	0.3%
Skin involvement	1.40 (0.67-3.09)	80.9%	19.1%
Pseudofolliculitis	1.07 (0.52-2.18)	56.5%	43.5%
Erythema nodosum	0.90 (0.41-2.29)	48.07%	51.93%
Other types of skin rash	0.17 (0.01-1.17)	4.05%	95.95%
Caucasic	2.45 (0.99-6.66)	97.42%	2.58%
Hispanic	0.81 (0.04-7.38)	48.0%	52.0%
Arab	0.5 (0.16-1.32)	9.22%	90.78%

#, Available in 78 patients.

Specifically, the table reports the odds ratio (OR, i.e., the exponentiated beta estimate), the 95% credibility interval (95% CrI), and the probabilities that the singularly assessed variable is either associated with $P(\beta > 0)$ or protective against $P(\beta < 0)$ intestinal involvement. All regressions are adjusted for the maximum disease duration and the use of immunosuppressive therapies. BDCAF, Behçet's Disease Current Activity Form. In bold values that have a significant posterior probability (beta>97.5%).

evaluating the risk of developing intestinal involvement among the most represented ethnic groups in this cohort, Caucasian ethnicity showed a trend toward a significant association with intestinal manifestations. Indeed, although the conventional threshold for statistical significance was not entirely satisfied, the association was nonetheless supported, with a posterior Bayesian probability of 97.42%.

Based on the marginal estimates obtained in the present study, suffering from exclusively minor aphthosis reduces the probability of developing gastrointestinal involvement by approximately 10%, whereas the presence of major aphthosis increases this probability by nearly 20%. The combination of major aphthosis and pseudofolliculitis further increases the risk to 21%, while patients presenting with major aphthosis, pseudofolliculitis, and genital aphthosis show an estimated 32% increase in the probability of developing gastrointestinal involvement. The association between major oral aphthosis and genital aphthosis alone also remains significantly correlated with intestinal inflammation, with an increased risk of approximately 17%. Therefore, major oral aphthosis represents the most robust predictor of intestinal involvement, as it consistently appears as the shared component in all statistically significant associations related to mucocutaneous manifestations. Despite the wide 95% CrI associated with the limited number of affected patients, the association of pseudofolliculitis with cutaneous manifestations distinct from erythema nodosum also appears to confer a protective effect against the development of intestinal involvement.

Noteworthy, current studies show that HLA-B51 is linked to a decreased prevalence of gastrointestinal involvement in BD (17). Interestingly, although not statistically significant, the present study shows a trend toward an association between HLA-B51 positivity and intestinal involvement in mucocutaneous-onset BD. Notably, the probability of an association between HLA-B51 positivity and the subsequent development of intestinal involvement is 97.2%, with a credibility interval approaching statistical significance. This discrepancy may be partly explained by the different ethnicities included in the previous studies, as they were predominantly conducted in Japanese and Korean cohorts (18–21). Alternatively, it might reflect a different role of HLA-B51 in the subgroups of BD patients with isolated mucocutaneous involvement in the early stages of the disease.

A positive family history is frequently observed in paediatric BD patients, and within the paediatric setting, an increased prevalence

TABLE 3 Results of Bayesian regression analyses evaluating the association between intestinal involvement (dependent variable) and different combinations of mucocutaneous manifestations of Behçet's disease (independent variable).

Combination of at least two mucocutaneous features	OR (1-95%CI)	p ($\beta > 0$)	p ($\beta < 0$)
Minor oral aphtosis + Genital Aphthosis	0.70 (0.32-1.50)	19.05%	80.95%
Minor oral aphtosis + Pseudofolliculitis	0.45 (0.15-1.21)	6.05%	93.95%
Minor oral aphtosis + Erythema nodosum	1.06 (0.34-2.99)	56.62%	43.38%
Minor oral aphtosis + Other types of skin rash	0.01 (0.0-1.06)	2.63%	97.37%

(Continued)

TABLE 3 Continued


Combination of at least two mucocutaneous features	OR (1-95%CI)	p ($\beta > 0$)	p ($\beta < 0$)
Major oral aphthous ulcerations + Genital Aphthosis	2.77 (1.14-6.58)	98.45%	1.55%
Major oral aphthous ulcerations + Pseudofolliculitis	3.18 (1.15-8.33)	98.72%	0.18%
Major oral aphthous ulcerations + Erythema nodosum	2.37 (0.66-7.77)	92.0%	8.0%
Genital Aphthosis + Pseudofolliculitis	1.52 (0.74-3.10)	88.2%	11.8%
Genital Aphthosis + Erythema nodosum	1.02 (0.37-2.52)	52.57%	47.48%
Genital Aphthosis + Infrequent skin rash	0.23 (0.01-1.63)	9.12%	90.88%
Pseudofolliculitis + Erythema nodosum	0.33 (0.05-1.40)	7.82%	92.18%
Pseudofolliculitis + Infrequent skin rash	0.01 (0.0-0.98)	2.45%	97.55%
Minor oral aphthosis + Genital Aphthosis + Pseudofolliculitis	0.47 (0.13-1.45)	9.77%	90.23%
Minor oral aphthosis + Genital Aphthosis + Erythema nodosum	1.63 (0.49-4.97)	80.82%	19.18%
Major oral aphthous ulcerations + Genital Aphthosis + Pseudofolliculitis	5.22 (1.71-16.35)	99.77%	0.33%
Genital Aphthosis + Pseudofolliculitis + Erythema nodosum	0.44 (0.06-1.94)	15.42%	84.57%
Minor oral aphthosis + Genital Aphthosis + Pseudofolliculitis + Erythema nodosum	0.32 (0.01-2.43)	17.57%	82.43%

The table reports the odds ratio (OR, i.e., the exponentiated beta estimate), the 95% credibility interval (95% CrI), and the probabilities that the mucocutaneous combinations are either associated with $P(\beta > 0)$ or protective against $P(\beta < 0)$ intestinal involvement. All regressions are adjusted for the maximum disease duration and the use of immunosuppressive therapies. Only combinations of mucocutaneous manifestations observed in at least 10 patients were included in the statistical analysis. In bold values that have a significant posterior probability (beta > 97.5%).

of gastrointestinal involvement has also been documented (22). In this study, a trend emerged linking a positive family history of BD to an increased risk of intestinal involvement in patients with an exclusively mucocutaneous disease onset. Specifically, the estimated probability of developing intestinal involvement increases by nearly

11% in patients with a positive family history compared to those without a familial background of BD.

Some study limitations should be acknowledged. Although the overall sample size was adequate, stratification by clinical features reduced the effective size of each subgroup. Using Bayesian statistics



helped address this limitation more effectively than a traditional frequentist approach. As with all multicenter registry studies, variability in data collection is inevitable; however, internationality also reduces referral bias and enhances the representativeness of the study population. Intestinal involvement in this cohort was heterogeneous, ranging from recurrent abdominal pain with elevated faecal calprotectin to endoscopically confirmed mucosal lesions. For this reason, intestinal involvement was uniformly defined as the presence of inflammation and/or ulceration in the gastrointestinal tract, and all findings of the present study should be interpreted in light of this definition. The pathergy test was excluded from the analysis due to its inconsistent execution across centers, which limits its reliability (23–25). Also, the stratification of oral ulcers according to discrete numerical categories of lesion count (1–2, 3–5, >5) was not based on a validated classification system but was pragmatically defined according to the distribution of cases in our cohort, in order to avoid very small subgroups and preserve analytical interpretability. Finally, the precise time ranging between BD onset and the occurrence of gastrointestinal involvement was not reported in most of the patients and this information was not provided.

In conclusion, this study identifies major aphthosis as the strongest factor associated with the developing of intestinal involvement among BD patients initially presenting with exclusively mucocutaneous manifestations. The coexistence of major aphthosis with pseudofolliculitis, especially when genital aphthosis is also present, further increases the likelihood of intestinal involvement. Conversely, the presence of minor aphthosis alone appears to reduce the probability of developing intestinal involvement, as does pseudofolliculitis when occurring alongside cutaneous manifestations other than erythema nodosum. Finally, intestinal involvement is associated with the development of ocular inflammation, suggesting that in patients initially presenting with isolated mucocutaneous manifestations, the emergence of one may be concomitant with or predictive of the other.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The Ethics Committee of Azienda Ospedaliero-Universitaria Senese, Siena, Italy (Ref. N. 14951; NCT05200715) approved the study, which was performed according to the Good Clinical Practice guidelines and the latest Declaration of Helsinki. Written informed consents for involved patients were collected. Clinical data are kept in accordance with the EU General Data Protection Regulations (GDPR), or other counterparts, on the processing of personal data and the protection of privacy (2016/679/EU).

Author contributions

AV: Writing – original draft, Writing – review & editing. VC: Writing – review & editing. JSb: Writing – review & editing. FrG: Writing – review & editing. GL: Writing – review & editing. GR: Writing – review & editing. SG: Writing – review & editing. IA: Writing – review & editing. AT: Writing – review & editing. RG: Writing – review & editing. HD: Writing – review & editing. PR: Writing – review & editing. GH: Writing – review & editing. FCa: Writing – review & editing. EDB: Conceptualization, Project administration, Formal analysis, Supervision, Methodology, Writing – review & editing, Validation, Investigation, Software, Data curation, Funding acquisition, Visualization, Resources. SO: Writing – review & editing. JSO: Writing – review & editing. HG: Writing – review & editing. MF: Writing – review & editing. PPS: Writing – review & editing. MM: Writing – review & editing. FeG: Writing – review & editing. AMa: Writing – review & editing. AA-MM: Writing – review & editing. RD: Writing – review & editing. HK: Writing – review & editing. RK: Writing – review & editing. IC: Writing – review & editing. LDC: Writing – review & editing. FAÖ: Writing – review & editing. GS: Writing – review & editing. MGe: Writing – review & editing. AKa: Writing – review & editing. AA: Writing – review & editing. HE: Writing – review & editing. FCr: Writing – review & editing. MTe: Writing – review & editing. FCi: Writing – review & editing. MTh: Writing – review & editing. SB: Writing – review & editing. AM: Writing – review & editing. MSC: Writing – review & editing. BM: Writing – review & editing. MP: Writing – review & editing. AF: Writing – review & editing. AH-A: Writing – review & editing. GG-B: Writing – review & editing. CC: Writing – review & editing. JH-R: Writing – review & editing. MC: Writing – review & editing. MGo: Writing – review & editing. OV: Writing – review & editing. ACi: Writing – review & editing. DO-B: Writing – review & editing. CG: Writing – review & editing. RT: Writing – review & editing. AG: Writing – review & editing. GE: Writing – review & editing. PSP: Writing – review & editing. MCM: Writing – review & editing. PPa: Writing – review & editing. PPO: Writing – review & editing. AD-L-T: Writing – review & editing. JC-L: Writing – review & editing. SGe: Writing – review & editing. AM: Writing – review & editing. GDS: Writing – review & editing. MFG: Writing – review & editing. AŞ: Writing – review & editing. DR: Writing – review & editing. EBi: Writing – review & editing. EDG: Writing – review & editing. LB: Writing – review & editing. ADP: Writing – review & editing. ALG: Writing – review & editing. ŞE: Writing – review & editing. ST: Writing – review & editing. LF: Writing – review & editing. MA: Writing – review & editing. AIn: Writing – review & editing. AK: Writing – review & editing. ACo: Writing – review & editing. ÖG: Writing – review & editing. AMo: Writing – review & editing. FLG: Conceptualization, Resources, Funding acquisition, Formal analysis, Validation, Project administration, Supervision, Investigation, Methodology, Software, Data curation, Writing – review & editing, Visualization. SC: Visualization, Investigation, Resources, Software, Conceptualization, Funding acquisition,

Supervision, Project administration, Data curation, Writing – review & editing, Formal analysis, Methodology, Validation. EBA: Writing – review & editing. PB: Writing – review & editing. SGU: Writing – review & editing. AG-G: Writing – review & editing. IR: Writing – review & editing. GC: Writing – review & editing. AIA: Writing – review & editing. FÖ: Writing – review & editing. SA-M: Writing – review & editing. AH: Writing – review & editing. AB: Writing – review & editing. CF: Writing – review & editing. LC: Project administration, Writing – review & editing, Supervision.

Funding

The author(s) declared that financial support was not received for this work and/or its publication.

Acknowledgments

This research is supported (not financially) by the European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (RITA) of the authors of this publication (AV, VC, JSb, JSo, SGe, AB, Bruno Frediani, CF LC, and JH-R) belong to institutes that are members of the ERN RITA (Azienda Ospedaliero-Universitaria Senese of Siena; Hospital Clínic of Barcelona).

References

- EmmiG, BettiolA, HatemiG, PriscoD. Behçet's syndrome. *Lancet*. (2024) 403:1093–108. doi: 10.1016/S0140-6736(23)02629-6
- Davatchi F, Shams H, et al. Behçet's disease: epidemiology, clinical manifestations, and diagnosis. *Expert Rev Clin Immunol*. (2017) 13:57–65. doi: 10.1080/1744666x.2016.1205486
- IdeguchiH, SudaA, TakenoM, UedaA, OhnoS, IshigatsuboY. Behçet disease: evolution of clinical manifestations. *Med (Baltimore)*. (2011) 90:125–32. doi: 10.1097/MD.0b013e318211bf28
- Alpsoy E, Bozca BC, Bilgic A. Behçet disease: an update for dermatologists. *Am J Clin Dermatol*. (2021) 22:477–502. doi: 10.1007/s40257-021-00609-4
- Valenti S, Gallizzi R, De Vivo D, et al. Intestinal Behçet and Crohn's disease: two sides of the same coin. *Pediatr Rheumatol Online J*. (2017) 15:33. doi: 10.1186/s12969-017-0162-4
- Cheon JH, Kim WH. An update on the diagnosis, treatment, and prognosis of intestinal Behçet's disease. *Curr Opin Rheumatol*. (2015) 27:24–31. doi: 10.1097/bor.0000000000000125
- Skef W, Hamilton MJ, Arayssi T. Gastrointestinal Behçet's disease: a review. *World J Gastroenterol*. (2015) 21:3801–12. doi: 10.3748/wjg.v21.i13.3801
- KasaharaY, TanakaS, NishinoM, UmemuraH, ShirahaS, KuyamaT. Intestinal involvement in Behçet's disease: review of 136 surgical cases in the Japanese literature. *Dis Colon Rectum*. (1981) 24:103–6. doi: 10.1007/BF02604297
- VitaleA, Della CasaF, LopalcoG, PereiraRM, RuscittiP, GiacomelliR, et al. Development and implementation of the AIDA International Registry for patients with Behçet's disease. *Intern Emerg Med*. (2022) 17:878797. doi: 10.3389/fmed.2022.878797
- International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. *Lancet*. (1990) 335:1078–80.
- International Team for the Revision of the International Criteria for Behçet's Disease (ITR-ICBD). The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. *J Eur Acad Dermatol Venereol*. (2014) 28:338–47. doi: 10.1111/jdv.12107
- LawtonG, BhaktaBB, ChamberlainMA, TennantA. The Behçet's disease activity index. *Rheumatol (Oxford)*. (2004) 43:73–8. doi: 10.4337/9780857937056.00017
- Randall DA, Wilson Westmark NL, Neville BW. Common oral lesions. *Am Fam Physician*. (2022) 105:369–76.
- HouCC, LuoD, BaoHF, YeJF, MaHF, ShenY, et al. Clinical heterogeneity of ocular Behçet's syndrome versus intestinal Behçet's syndrome: a cross-sectional study from Shanghai Behçet's syndrome database. *Arthritis Res Ther*. (2022) 24:98. doi: 10.1186/s13075-022-02782-1
- Manuelyan Z, Butt E, Parupudi S. Gastrointestinal Behçet's disease: manifestations, diagnosis, and management. *Dis Mon*. (2024) 70:101674. doi: 10.1016/j.disamonth.2023.101674
- HouCC, YeJF, MaHF, GuanJL. Clinical characteristics and risk factors of intestinal involvement in Behçet's syndrome patients: a cross-sectional study from a single center. *Orphanet J Rare Dis*. (2021) 16:132. doi: 10.1186/s13023-021-01772-x
- MaldiniC, LavalleyMP, CheminantM, de MenthonM, MahrA. Relationships of HLA-B51 or B5 genotype with Behçet's disease clinical characteristics: systematic review and meta-analyses of observational studies. *Rheumatol (Oxford)*. (2012) 51:887–900. doi: 10.1093/rheumatology/ker428
- MizukiY, HoritaN, HorieY, TakeuchiM, IshidoT, MizukiR, et al. The influence of HLA-B51 on clinical manifestations among Japanese patients with Behçet's disease: a nationwide survey. *Mod Rheumatol*. (2020) 30:708–14. doi: 10.1080/14397595.2019.1649103
- RyuHJ, SeoMR, ChoiHJ, BaekHJ. Clinical phenotypes of Korean patients with Behçet disease according to gender, age at onset, and HLA-B51. *Korean J Intern Med*. (2018) 33:1025–31. doi: 10.3904/kjim.2016.202
- KirinoY, IdeguchiH, TakenoM, SudaA, HigashitaniK, KunishitaY, et al. Continuous evolution of clinical phenotype in 578 Japanese patients with Behçet's disease: a retrospective observational study. *Arthritis Res Ther*. (2016) 18:217. doi: 10.1186/s13075-016-1115-x
- SoejimaY, KirinoY, TakenoM, KurosawaM, TakeuchiM, YoshimiR, et al. Changes in the proportion of clinical clusters contribute to the phenotypic evolution of Behçet's disease in Japan. *Arthritis Res Ther*. (2021) 23:49. doi: 10.1186/s13075-020-02406-6

Conflict of interest

The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declared that generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

22. Shahram F, Nadjia A, Akhlaghi M, Faezi S T, Chams-Davatchi C, Shams H, et al. Paediatric Behçet's disease in Iran: report of 204 cases. *Clin Exp Rheumatol*. (2018) 36:135–40.
 23. Shenavandeh S, Sadeghi SMK, Aflaki E. Pathergy test with a 23G needle with and without self-saliva in patients with Behçet's disease, recurrent aphthous stomatitis and control group compared to the 20G test. *Reumatologia*. (2021) 59:302–08. doi: 10.5114/reum.2021.110567
 24. Kalay Yildizhan İ, Boyvat A. Diagnostic sensitivity of different applications of pathergy test for Behçet's disease. *Arch Rheumatol*. (2019) 35:29–34. doi: 10.5606/archrheumatol.2020.7380
 25. Vitale A, Berlengiero V, Caggiano V, Barneschi S, Mourabi M, Sota J, et al. The diagnostic role of pathergy test in patients with Behçet's disease from the Western Europe. *Intern Emerg Med*. (2023) 18:77–83. doi: 10.1007/s11739-022-03117-3
- COPYRIGHT
 © 2026 Vitale, Caggiano, Sbalchiero, Gavioli, Lopalco, Ragab, Guerriero, Almaglouth, Tufan, Giacomelli, Direskeneli, Ruscitti, Hatemi, Carubbi, Batu, Ozen, Sota, Giardini, Frassi, Sfrikakis, Morrone, Gatti, Maher, Mahmoud, Dammacco, Kucuk, Kardas, Cakir, Corcia, Öner, Sevik, Gentile, Karakoc, Alunno, Emreol, Crisafulli, Tektonidou, Ciccio, Thabet, Bugatti, Milanese, Chimenti, Monosi, Piga, Floris, Hinojosa-Azaola, Guaracha-Basañez, Chighizola, Hernández-Rodríguez, Cattalini, Govoni, Viapiana, Civino, Opris-Belinski, Gaggiano, Talarico, Giardina, Emmi, Puttini, Maggio, Parronchi, Portincasa, de-la-Torre, Cardona-López, Gentileschi, Mauro, Sebastiani, Gicchino, Şahin, Rigante, Bilgin, Del Giudice, Breda, De Paulis, Lo Gullo, Erten, Tharwat, Fotis, Armin, Insalaco, Karamanakis, Conforti, Gündüz, Moshirif, Li Gobbi, Costi, Bartoloni, Barone, Guiducci, González-García, Rodríguez, Conti, Iagnocco, Önen, Al-Mayouf, Hatemi, Balistreri, Fabiani and Cantarini. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.